buyModerate
Krishna Yeshwant bought $18M of VERV
director, owner at Verve Therapeutics, Inc.. 1,800,000 shares at an average of $10.00, traded Dec 1, 2023, filed Dec 5, 2023.
Conviction score
48Value
$18M
1,800,000 shares
Holdings after
1,800,000
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$18.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-068199, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | POpen-market purchase Common Stockindirect: By GV 2023, L.P. | +1,800,000 | $10.00 | $18M | 1,800,000 | Dec 5, 2023 |
Related signals
Other insiders at Verve Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $11k 2,681 shares | -1% | |
| 7Weak | Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $14k 3,350 shares | -20% | |
| 11Weak | Verve Therapeutics, Inc. | Sekar Kathiresan Chief Executive Officer | $41k 9,822 shares | -3% | |
| 0Weak | Verve Therapeutics, Inc. | Troy Lister Chief Scientific Officer | $9,084 2,189 shares | -24% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 2,777 shares | -14% | |
| 0Weak | Verve Therapeutics, Inc. | Jason Politi Chief Technical Ops. Off. | $13k 3,235 shares | -19% | |
| 7Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $3,130 555 shares | -9% | |
| 39Weak | VERVbuy Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $476k 76,000 shares | +29% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 1,514 shares | -15% | |
| 12Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $6,343 554 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.